Document is current
Any future updates will be listed below
-
Authors
Muraoka, Shinsuke https://orcid.org/0000-0003-4225-110X
Izumi, Takashi
Ishii, Kazuki
Takeuchi, Issei
Nishihori, Masahiro
Goto, Shunsaku
Kanamori, Fumiaki
Uda, Kenji
Sakamoto, Yusuke
Yokoyama, Kinya
Nishida, Kazuki
Chretien, Basile
Saito, Ryuta
-
Funding
Funding for this research was provided by:
Nagoya University
- License Information
-
More Information
Article History
Received: 15 April 2025
Revised: 5 August 2025
Accepted: 18 September 2025
First Online: 10 October 2025
Declarations
:
: This study was conducted in accordance with the 1964 Declaration of Helsinki and its later amendments and approved by the Institutional Review Board (IRB) of Nagoya University Hospital (approval number: 2022 − 0476). Informed consent was waived as the analysis used anonymized clinical data collected after obtaining written informed consent for treatment. Additionally, patient approval was obtained via an IRB-approved opt-out poster displayed in the outpatient department and neurosurgery ward.
: All authors have read and agreed to the published version of the manuscript, and consent to its publication.
: The last author, Professor Ryuta Saito, received research funding from Nxera Pharma Japan, the distributor of clazosentan. However, Professor Saito was not involved in the planning or analysis of this study and contributed solely in supervisory capacity. The other authors did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
